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Summary
Objective: Peroxynitrite (ONOO) is formed in the inﬂamed and degenerating human joint. Peroxynitrite-modiﬁed collagen-II (PMC-II) was re-
cently discovered in the serum of patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Therefore we investigated the cellular effects
of PMC-II on human mesenchymal progenitor cells (MPCs) as a model of cartilage and cartilage repair cells in the inﬂamed and degenerating
joint.
Design: MPCs were isolated from the trabecular bone of patients undergoing reconstructive surgery and were differentiated into a chondro-
genic lineage. Cells were exposed to PMC-II and levels of the proinﬂammatory mediators nitric oxide (cNO) and prostaglandin E2 (PGE2) mea-
sured. Levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), phosphorylated mitogen activated protein kinases
(MAPKs) and nuclear factor kappa B (NF-kB) activation were measured by enzyme linked immunosorbent assay (ELISA) together with spe-
ciﬁc MAPK and NF-kB inhibitors.
Results: PMC-II induced cNO and PGE2 synthesis through upregulation of iNOS and COX-2 proteins. PMC-II also lead to the phosphorylation
of MAPKs, extracellularly regulated kinase 1/2 (ERK1/2) and p38 [but not c-Jun NH2-terminal kinase (JNK1/2)] and the activation of proinﬂam-
matory transcription factor NF-kB. Inhibitors of p38, ERK1/2 and NF-kB prevented PMC-II induced cNO and PGE2 synthesis, iNOS and COX-2
protein expression and NF-kB activation.
Conclusion: iNOS, COX-2, NF-kB and MAPK are known to be activated in the joints of patients with OA and RA. PMC-II induced iNOS and
COX-2 synthesis through p38, ERK1/2 and NF-kB dependent pathways suggesting a previously unidentiﬁed pathway for the synthesis of the
proinﬂammatory mediators, cNO and PGE2, further suggesting that inhibitors of these pathways may be therapeutic in the inﬂamed and de-
generating human joint.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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An overproduction of nitric oxide (cNO) and reactive oxygen
species (ROS) such as superoxide (O2
c) is implicated in the
pathology of various rheumatoid, inﬂammatory and degen-
erative joint diseases (reviewed in Refs. 1e7). The interac-
tion of cNO and O2
c forms the cytotoxic product peroxynitrite
(ONOO; Eq. 1)8.
cNOþO2c/ONOO
461Osteoarthritis and Cartilage Vol. 14, No. 5The rate constant for this reaction is greater than
109 M1 s1 (Ref. 8) and under conditions of increased
NO production, such as the inﬂamed rheumatoid joint1e4
or osteoarthritic cartilage5e7 cNO competes with superoxide
dismutase (SOD) for O2
c resulting in ONOO formation8.
Under physiological conditions ONOO has a half life of un-
der 1 s and it is converted to its protonated form, peroxyni-
trous acid (ONOOH), which in turn decays to generate
multiple toxic products with reactivities resembling those
of the nitryl cation (NO2
þ), nitrogen dioxide radical (cNO2)
and hydroxyl radical (cOH). ONOO and species derived
from it oxidize lipids, proteins, DNA and carbohydrates9e11
and the addition of ONOO to biological ﬂuids leads to the
depletion of endogenous antioxidants such as ascorbate,
urate and thiols12. Oxidized lipids, proteins, DNA and carbo-
hydrates as well as antioxidant depletion have all been
measured in OA and RA patients1,2,4,6,7. Therefore it is pos-
sible that some of these biomarkers of ROS observed in
rheumatoid arthritis (RA) are not only attributed to elevated
ROS and oxidative stress but also to ONOO, resulting in
nitrosative stress.
Consistent with nitrosative stress in inﬂammatory and de-
generative joint diseases, increased levels of cNO [mea-
sured as the stable end products of NO-metabolism,
nitrite (NO2
) and nitrate (NO3
)13] have been detected in
sera, plasma and synovial ﬂuids2e6 of OA and RA patients.
In addition to invading inﬂammatory phagocytes, cells within
the human joint such as articular chondrocytes, panno-
cytes, synovial ﬁbroblasts, synovial macrophages, osteo-
blasts and osteoclasts (reviewed in Ref. 3) are capable of
synthesizing micromolar quantities of NO contributing to
the elevated levels of NO2
 observed. Inducible nitric oxide
synthase (iNOS) has been associated with chondrocytes
during the pathogenesis of osteoarthritis (OA)14 and RA15,
and inhibitors of iNOS16,17 and ONOO18,19 have been
shown to reduce joint inﬂammation and erosion in animal
models of these pathologies. Additionally, ONOO reacts
with the amino acid tyrosine to form a nitrated biomarker,
3-nitrotyrosine (reviewed in Refs. 20,21). Increased levels
of this nitrated amino acid have been observed in sera
and synovial ﬂuid of rheumatoid patients22 and immunohis-
tochemistry for 3-nitrotyrosine containing proteins has de-
tected extensive tyrosine nitration in the cartilage, synovial
ﬂuid, synovial and endothelial tissue of patients with
OA23e26 and RA23,24 as well as in the cartilage of aging hu-
mans25. Furthermore, apoptotic chondrocytes in OA and
RA cartilage are reported to contain 3-nitrotyrosine23 and
the addition of ONOO to articular chondrocytes leads to
apoptotic death27. However, these studies only conﬁrmed
the presence of nitrated proteins rather than their identity.
Recently, Deberg et al.28, using a novel immunoassay, dis-
covered markedly elevated levels of nitrated collagen-II in
the serum of patients with OA and RA where it was present
as positively correlated levels of C-reactive protein suggest-
ing nitrated collagen-II may act as a novel biomarker for re-
active nitrogen species (RNS) and might be involved in the
inﬂammatory process28.
In addition to producing cNO through iNOS, chondrocytes
can also be induced to synthesize high concentrations of
the proinﬂammatory mediator prostaglandin E2 (PGE2)
through the inducible enzyme cyclooxygenase-2 (COX-2)
(reviewed in Refs. 29e31). Increased levels of PGE2 and
COX-2 have been reported in synovial ﬂuids from OA-af-
fected and RA-affected joints and inhibitors of COX-2
have been extensively studied for their anti-inﬂammatory ef-
fects29e31. The synthesis of iNOS and COX-2 inducible en-
zymes is regulated by the transcription factor nuclear factorkappa B (NF-kB) and the mitogen activated protein kinases
(MAPKs; reviewed in Refs. 32e35). For example, activation
of NF-kB is observed in the inﬂamed synovium and sur-
rounding tissues in arthropathies36e38, MAPKs are activated
in joint diseases39 and inhibitors of MAPK prevent NF-kB
activation and induction of iNOS and COX-2 in animal mod-
els of arthritis40e46. Furthermore, inhibitors of NF-kB also
reduce joint swelling and joint erosion in experimental mod-
els of arthritis47 and inﬂammation48 as well as reduce the
protein levels of iNOS and COX-2 and ONOO formation,
measured as 3-nitrotyrosine49.
Chondrocytes are a differentiated cell type derived from
mesenchymal progenitor cells (MPCs) whose pluripotential
nature results in progeny that include osteoblasts, bone
marrow stromal cells, adipocytes, myocytes and tendon
cells50. Synovial ﬂuid effusions from OA or RA patients con-
tain immature mesenchymal cells and normal adult carti-
lage was recently shown to contain MPCs capable of
chondrogenic differentiation with an increased quantity of
these cells detected in cartilage from OA patients51. Al-
though this has yet to be investigated in RA patients, it
strongly suggests that MPCs have a role in cartilage repair
and pathological cartilage remodeling in various arthropa-
thies. These MPCs are also likely to be exposed to the initial
cartilage damaging agent(s) in arthropathies and so their
fate in the degenerating human joint is as important as
that as the cells they are replacing and when differentiated
into the chondrogenic lineage these cells provide a useful
model for studying chondrocyte function51e54.
Therefore, in the present study we used cultured human
MPCs differentiated into a chondrogenic lineage as a model
of cartilage and cartilage repair cells exposed to ONOO-
modiﬁed collagen. For the ﬁrst time, our results show perox-
ynitrite-modiﬁed collagen-II (PMC-II) induced substantial
cNO and PGE2 formation through a MAPK/NF-kB-depen-
dent pathway and represent a novel mechanism for RNS
and eicosanoid formation in the inﬂamed and degenerating
human joint.
Materials and methods
MATERIALS
Phospho-extracellularly regulated kinase 1/2 (#KHO0091),
phospho-c-Jun NH2-terminal kinase (#KHO0121), and
phospho-p38 (#KHO0071) enzyme linked immunosorbent
assay (ELISA) kits were purchased from BioSource Interna-
tional (Camarillo, CA, USA). PGE2 (#514010) ELISA kits
were purchased from Cayman Chemical Corporation (Ann
Arbor, MI, USA). TransAM NF-kB chemiluminescence as-
say was purchased from Active Motif (#400096; Carlsbad,
CA, USA), human COX-II ELISA was purchased from As-
say Designs (#900-094; Ann Arbor, MI, USA) and human
iNOS ELISA was purchased from R and D Systems
(#DNS00; Minneapolis, MN, USA). Amplex Red hydrogen
peroxide assay was purchased from Molecular Probes
(#A22188; Eugene, OR, USA). Inhibitors of p38 [(RS )-{4-
[5-(4-ﬂuorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]pyri-
din-2-yl}-(1-phenylethyl)amine (ML3403)], extracellularly
regulated kinase 1/2 (ERK1/2) [Ste-MPKKKPTPIQLNP-
NH2 (Ste-MEK113)], c-Jun NH2-terminal kinase (JNK1/2)
[anthra[1,9-cd]pyrazol-6(2H )-one (SP600125)], COX-2
(NS-398), iNOS (1400W) and NF-kB [2-benzoylamino-1,
4-naphthoquinone (PPM-18)] were purchased from Calbio-
chem, San Diego, CA, USA. 3-Nitrotyrosine ELISA (#HK-
501) was purchased from Cambridge Biosciences (Cam-
bridge, England). Collagen-II antibody was purchased
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L-modiﬁed collagen-IIfrom Southern Biotechnology Associates Inc. (Birmingham,
AL, USA). Human collagen type II was purchased from US
Biological (Swampscott, MA, USA), and fatty acid-free albu-
min and all other reagents were purchased from Sigmae
Aldrich (St. Louis, MO, USA).
EQUIPMENT
Gemini EM ﬂuorescence, LMax luminescence and Spec-
traMax 190 microplate readers (Molecular Devices, Sunny-
vale, CA, USA) were used for ﬂuorescence, luminescence
and UVevisible measurements, respectively.
SYNTHESIS OF ONOO AND EXPOSURE OF PROTEINS
TO ONOO
Hydrogen peroxide-free ONOO was synthesized as de-
scribed55 and hydrogen peroxide removal conﬁrmed using
a commercial kit (Amplex Red, Molecular Probes). ONOO
concentration was quantiﬁed in 1 M NaOH at 302 nm
(3¼ 1670 M1 cm1)56. Human collagen-II was prepared
as described in Refs. 57,58. To generate ONOO-modiﬁed
protein, protein was incubated at 37(C for 15 min and in-
creasing concentrations of ONOO added (100 mMe1 mM).
Since ONOO decomposes at physiological pH (t1/2<
1 min) to give NO2
 and NO3
, control experiments using
decomposed ONOO, prepared as described in Ref. 55
was added to the protein solution. The addition of ONOO
or decomposed ONOO did not signiﬁcantly alter the pH of
the reaction mixture. Human albumin was used and treated
under the exact conditions as collagen-II and was used as
a control protein since albumin is known to be readily oxi-
dized and nitrated by ONOO (Ref. 59).
ISOLATION OF THE CELLS AND LINEAGE SPECIFIC
DIFFERENTIATION CONDITIONS
MPCs were isolated from the trabecular bone of patients
undergoing reconstructive surgery54. This study was ap-
proved by the ethics committee of the National University
Hospital and National University of Singapore and informed
written consent was obtained from each patient. MPCs
were differentiated into chondrogenic lineage as is the rou-
tine in our laboratory and described in Ref. 54. Cells were
centrifuged and 1 106 cells were seeded into 48 well
plates (Greiner) containing Ham’s F-12 media containing
2 mM glutamine, 2 mM dexamethasone, ascorbic acid 2
phosphate (50 mg/ml), 1 mM sodium pyruvate, proline
(40 mg/ml), transforming growth factor beta 3 (10 ng/ml)
and 5 ml/500 ml media of ITSþ 3 (SigmaeAldrich) at a ﬁnal
concentration of 6.25 mg/ml. Chondrogenic lineage was
conﬁrmed by microscopic evaluation, staining for glycos-
aminoglycan production (alcian blue and safranin O stain-
ing) as well as the analysis for the presence of
collagen type II in culture media and cell lysates by Western
blotting.
ASSESSMENT OF CELL VIABILITY
Metabolic activity was estimated using 3-(4,5-dimethyl-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) and data are
expressed as % of untreated cells27. Leakage of lactate de-
hydrogenase (LDH) into the culture media was measured at
340 nm using a commercially available kit (CytoTox96, Mo-
lecular Probes) and data are expressed as % LDH activity
from cells lysed with 0.1% Triton-X for 20 min at 37(C27.ONOO-INDUCED PROTEIN NITRATION AND PROTEIN
OXIDATION
Levels of protein nitration (3-nitrotyrosine; Cambridge
Biosciences) and protein oxidation (as protein carbonyls;
Zenith Technology) were quantiﬁed using commercial
ELISAs as described in Refs. 60e62.
MEASUREMENT OF iNOS/COX-2 PROTEINS
AND NO2
/PGE2 PRODUCTION
After the addition of ONOO-modiﬁed proteins, cells were
incubated overnight and media collected for NO2
 determi-
nation by Griess assay63 and PGE2 measurement using
a commercial EIA kit from Caymen Chemicals (#514010).
To investigate speciﬁc effects of iNOS or COX-2 activity,
control experiments using established inhibitors of iNOS
and COX-2 were also performed. Prior to the addition of
PMC-II, cells were incubated for 1 h in culture media con-
taining 1400W (1 mM) to inhibit iNOS64 or NS-398 (1 mM)
to inhibit COX-2 activity65. These concentrations were cho-
sen based on preliminary studies and under these condi-
tions did not signiﬁcantly reduce cellular viability
(measured with the MTT and LDH release assays). To fur-
ther demonstrate that any observed NO2
 or PGE2 formed
was due to iNOS and COX-2, levels of iNOS (#DNS00)
and COX-2 (#900-094) proteins were analyzed using com-
mercial ELISA from R and D Systems and Assay Designs,
respectively, using cell lysates prepared according to the
manufacturer’s instructions and using the manufacturer’s
reagents.
ASSESSMENT OF MAPK AND NF-kB ACTIVATION
To assess intracellular cell stress responses to PMC-II,
phosphorylations of the MAPKs ERK1/2, JNK1/2 and p38
were examined. Cells were treated with MAPK inhibitors
or equivalent volumes of dimethyl sulfoxide (0.01% v/v)
and ONOO-modiﬁed proteins added. These compounds
were used at concentrations previously reported in the liter-
ature and chosen based on their reported speciﬁcity. To in-
hibit the phosphorylation of ERK1/2, p38 and JNK1/2,
10 mM of Ste-MEK113
66, ML340367 and SP60012568 were
used. These inhibitors were chosen based on their reported
speciﬁcity and pharmacology; speciﬁcally, Ste-MEK113 is
a cell permeable stearated 13 amino acid peptide that cor-
responds to the N-terminus of MEK1, a kinase kinase [mito-
gen activated protein kinase kinase (MAPKK)] which
phosphorylates ERK1/266, therefore binding of Ste-
MEK113 to ERK1/2 inhibits ERK1/2 phosphorylation
66.
ML3403 is a cell permeable methylsulfanylimidazole that
binds to the adenosine triphosphate (ATP) binding site of
the MAPK p38 to inhibit p38 phosphorylation67 and
SP600125 is an ATP-competitive inhibitor of JNK1/268.
Thus, at the desired time, cells were lysed and analyzed
for MAPK phosphorylation using commercial ELISA kits ac-
cording to the manufacturer’s instructions and using re-
agents supplied with each kit69. To assess activation of
the transcription factor NF-kB, a commercial luminescence
kit was used (Active Motif) and nuclear extracts were pre-
pared using reagents supplied with the kit and used as de-
scribed by the manufacturer70. To inhibit the activation of
NF-kB, 10 mM of PPM-1871,72 was added prior to the addi-
tion of PMC-II since PPM-18 is reported to speciﬁcally pre-
vent the binding of the p50 and p65 subunits of NF-kB to
DNA by stabilizing the endogenous NF-kB inhibitor,
463Osteoarthritis and Cartilage Vol. 14, No. 5IkBa71,72, without interfering with additional proinﬂammatory
transcription factors such as AP-173.
STATISTICAL ANALYSIS
Data are expressed as mean standard deviation of the
mean (SD) of separate experiments (n 4) performed on
separate days using freshly prepared reagents. Where sig-
niﬁcance testing was performed, analysis of variance
(ANOVA) was used (*P< 0.05, **P< 0.01, ***P< 0.001)
and concentration-dependent effects were investigated
with post hoc Dunnett’s test using SPSS 12.0 software.
Results
CONFIRMATION OF CHONDROGENIC LINEAGE
IN DIFFERENTIATED MPCS
Chondrocytic phenotype was distinguished through mor-
phological features, collagen production and the formation
of extracellular matrix (ECM) components such as glycosa-
minoglycans. Figure 1 shows conﬁrmation of chondrocytic
differentiation, morphology [Fig. 1(A)], positive staining
with alcian blue [Fig. 1(B)] and safranin O [Fig. 1(C)] and
collagen-II production [Fig. 1(D)]. Thus, throughout this pa-
per we refer to the term ‘chondrocytic cells’ to describe
these differentiated cells.
CHARACTERIZATION OF THE CELLULAR RESPONSE
TO ONOO-MODIFIED PROTEINS
As expected59, the addition of ONOO to isolated pro-
teins led to the extensive formation of 3-nitrotyrosine
[Fig. 2(A)] and protein oxidation, measured as protein
carbonyl adducts [Fig. 2(B)] in a manner that increased
with increasing concentration of ONOO. A ONOO con-
centration of 125 mM was chosen for subsequent studies.
The addition of 1e60 mg/ml of collagen-II modiﬁed with
125 mM ONOO (PMC-II), ONOO-modiﬁed albumin or ve-
hicle treated collagen-II did not lead to signiﬁcant reduction
of cellular viability measured using MTT and LDH assays
[Fig. 3(A)] and a ﬁnal concentration of 30 mg/ml of PMC-II
was chosen for further studies.
Levels of NO2
 and PGE2 in the culture media from con-
trol cellswere 0.8 0.1 mMand7.5 3.1 ng/ml, respectively,
and the addition to cells of 30 mg/ml PMC-II led to the sig-
niﬁcant concentration-dependent formation of cNO (mea-
sured as NO2
) and PGE2 [Fig. 3(B)] measured in the
cell culture media 18 h postaddition. In sharp contrast,
the addition of either 125 mg/ml collagen-II or ONOO-
modiﬁed albumin did not lead to a signiﬁcant increase
in NO2
 (0.7 0.5 and 0.9 0.3 mM, respectively). Simi-
larly, nonmodiﬁed collagen-II or ONOO-modiﬁed albumin
did not signiﬁcantly increase the levels of PGE2 (6.8 0.6
and 6.5 1.0 ng/ml, respectively). Therefore, the addition
of ONOO-modiﬁed albumin (which contained nitrated ty-
rosine residues) or vehicle treated collagen-II (which was
not tyrosine nitrated) did not induce NO2
 or PGE2, thus
these data suggested that stimulation of NO2
 and PGE2
synthesis was speciﬁc to ONOO-induced collagen-II
modiﬁcation and not a general response to protein nitra-
tion or an effect of adding collagen-II to cells. The effect
of PMC-II was not attributed to cell death since the addi-
tion of 30 mg/ml PMC-II only led to 15.0 8.2% reduction
in cellular viability measured using the MTT assay
[Fig. 3(A)] and only 5.6 4.3% LDH activity comparedto Triton-X100 lysed cells. Pretreatment of cells with
COX-2 inhibitor NS-398 (1 mM) and iNOS inhibitor
1400W (1 mM) signiﬁcantly inhibited PGE2 and NO2
 for-
mation, respectively [Fig. 3(C)], suggesting that PMC-II in-
duced COX-2 and iNOS enzyme activity. To investigate
this further, we employed commercial ELISAs speciﬁc
for COX-2 and iNOS proteins. Figure 3(D) shows that
the addition of 30 mg/ml PMC-II led to a time-dependent in-
crease in the expression of iNOS and COX-2 proteins. Con-
trol experiments also showed that the addition of the
unmodiﬁed collagen-II or ONOO-modiﬁed albumin did not
result in the signiﬁcant increase in iNOSorCOX-2 protein lev-
els detected using the commercial ELISAs employed. Levels
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Fig. 1. Conﬁrmation of chondrogenic phenotype. MPCs were iso-
lated from trabecular bone and differentiated into a chondrogenic
lineage. Cell morphology was analyzed by light microscopy (A)
and production of ECM and proteoglycans was analyzed using al-
cian blue (B) and safranin O (C). Culture media and lysed cells
were analyzed for collagen-II by Western blotting (D). The pictures
shown are representative of experiments conducted on a daily
basis in our laboratory.
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Fig. 2. Characterization of ONOO-induced protein nitration and
oxidation. Proteins were exposed to increasing concentrations of
ONOO at pH 7.4 and levels of protein 3-nitrotyrosine (nitration)
and the extent of protein oxidation, measured as protein carbonyl
adducts, were determined by commercial ELISAs. Data are ex-
pressed as mean SD of four or more separate experiments.
**P< 0.05, ***P< 0.01 compared to untreated protein.of iNOS protein in control cells were 0.30 0.04 ng/ml
whereas after the addition of 125 mg/ml unmodiﬁed colla-
gen-II and ONOO-modiﬁed albumin for 8 h levels of iNOS
protein were 0.31 0.06 ng/ml and 0.29 0.05 ng/ml, re-
spectively. Similarly, levels of COX-2 protein in control cells
were 1.40 0.29 ng/ml whereas after the addition of
125 mg/ml unmodiﬁed collagen-II or ONOO-modiﬁed albu-
min for 8 h levels of COX-2 protein were 1.37 0.12 ng/ml
and 1.33 0.37 ng/ml, respectively.
PMC-II INDUCED MAPK ACTIVATION
Since the addition of 30 mg/ml of PMC-II was not cytotoxic
and induced the formation of signiﬁcant concentrations of
cNO and PGE2, inhibited by iNOS and COX-2 speciﬁc
drugs, and also led to the induction of iNOS and COX-2
(Fig. 3); we next investigated the possible mechanisms re-
sponsible for these phenomena. Production of cNO and
PGE2 and synthesis of iNOS and COX-2 proteins have
been reported to be controlled by MAPKs and the nuclear
transcription factor-kB (NF-kB).
Figure 4(A) shows that the addition of 30 mg/ml PMC-II to
cells resulted in a signiﬁcant phosphorylation of ERK1/20 25 50 75 100 125
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Fig. 3. Effect of PMC-II iNOS and COX-2 induction and activity. Cells were exposed for 18 h to 30 mg/ml ONOO-modiﬁed proteins and cell vi-
ability assessed byMTT assay (A). Cell culturemedia was analyzed for NO2
 (as an index of NO synthesis) using theGreiss assay and levels of
PGE2 determined by commercial ELISA (B). Inhibitors (10 mM) of iNOS (1400W) and COX-2 (NS-398) were added to cells for 1 h prior to the
addition of on NO2
 and PGE2 levels (C). Levels of iNOS and COX-2 proteins were determined over time and by ELISA (D). Data are expressed
as mean SD of four or more separate experiments. ***P < 0.01 compared to untreated cells (A, B and D) or PMC-II treated cells (C).
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Fig. 4. Effect of PMC-II on MAPK induction. Cells were exposed to 30 mg/ml PMC-II (PMC-II) for the times stated and levels of phosphorylated
MAPK were analyzed by ELISA. (A) Time course of MAPK phosphorylation induced by PMC-II. (B) Effect of p38 (ML3403), ERK1/2 (Ste-
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to the addition of PMC-II (30 mg/ml) subsequently added for 1 h. NO2
 and PGE2 levels in the cell culture media were measured by Greiss
assay or ELISA, respectively (C), and the levels of iNOS and COX-2 proteins measured by ELISA (D) after 8 h. The speciﬁcity of each inhibitor
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L-modiﬁed collagen-IIobserved at 10 min and phosphorylation of p38 observed at
30 min postaddition. In contrast, small but signiﬁcant
(P< 0.5) increases in phospho-JNK1/2 were only detected
60 min after the addition of PMC-II [Fig. 4(A)]. Control ex-
periments showed that the addition of inhibitors of p38
(ML3403), ERK1/2 (Ste-MEK113) and JNK1/2 (SP600125)
substantially prevented the phosphorylation of ERK1/2,
p38 and JNK1/2 [Fig. 4(B)]. To further investigate down-
stream signaling of PMC-II induced cNO and PGE2 produc-
tion, we next examined the effects of PMC-II on NF-kB
induction. Figure 5(A) shows that PMC-II induced the exten-
sive NF-kB activation in a time-manner with signiﬁcant acti-
vation observed after 4 h. The addition of speciﬁc inhibitors
of ERK1/2, p38 and NF-kB (PPM-18) and to a lesser extent
JNK1/2 (SP600125) substantially prevented PMC-II in-
duced NF-kB activation [Fig. 5(B)] and signiﬁcantly inhibited
cNO and PGE2 formation [Fig. 5(C)] suggesting that acti-
vations of these MAPKs were required for PMC-II induced
NF-kB activation. Preliminary experiments using the inhibi-
tors at the concentrations stated above showed that when
used individually these compounds did not induce signiﬁ-
cant cytotoxicity (MTT and LDH release) under our experi-
mental conditions (data not shown). However, when
SP600125, Ste-MEK113 and ML3403 were used together,
substantial and signiﬁcant cytotoxicity was observed (MTT
assay, 45.3 6.7% compared to vehicle control,
95.9 5.4%; LDH assay, 42.7 15.5% compared to Tri-
ton-X100 lysed cells, 100.25 12.8%). This observation
precluded us from investigating the effects of all three
MAPK inhibitors on PMC-II induced cell signaling.
Discussion
There is substantial evidence for an overproduction of
RNS in inﬂammatory and degenerative joint diseases
such as OA and RA. Elevated levels of cNO metabolites,
NO2
 and NO3
 are observed in sera and synovial ﬂuid
from OA and RA patients and extensive 3-nitrotyrosine for-
mation, a biomarker for ONOO is observed throughout the
diseased joint. Inhibitors of iNOS and scavengers of
ONOO have also shown considerable success in acute
and chronic inﬂammatory conditions as well as in experi-
mental models of OA. In addition to nitrating intracellular
protein tyrosine residues, RNS may also nitrate ECM com-
ponents such as collagen-II, an ECM component recently
detected in the serum of patients with OA and RA. Deberg
et al.28 very recently demonstrated the presence of a novel
RNS-dependent biomarker of ECM nitration in the serum
from OA and RA patients, nitrated collagen-II, and sug-
gested that nitration occurred through ONOO, an RNS
known to be formed in the inﬂamed and degenerating hu-
man joint. Since the cellular consequences of the formation
of this novel biomarker have yet to be demonstrated, we in-
vestigated the potential effects of this novel RNS-product on
chondrogenically differentiated MPCs as a model of carti-
lage and cartilage repair cells in the human joint. Recently,
Alsalameh et al.51 demonstrated the presence of MPCs ca-
pable of chondrogenic differentiation in the human joint and
that their number was substantially elevated in the joints of
OA patients suggesting a role of MPCs in cartilage repair.
Since these MPCs are also likely to be exposed to the initial
cartilage damaging agent(s) in arthropathies their fate in the
degenerating human joint is as important as that as the cells
they are replacing. Once differentiated into a chondrogenic
lineage these cells provide a useful tool for studying chon-
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Fig. 5. Effect of PMC-II on NF-kB activation. Cells were exposed to
30 mg/ml PMC-II for the times stated and levels of NF-kB were an-
alyzed by commercial ELISA in nuclear pellets prepared using re-
agents supplied with the kit. (A) Time course of PMC-II induced
NF-kB activation. (B) Inhibitors of NF-kB (PPM-18) and MAPK
(p38, ML3403; ERK1/2, Ste-MEK113; JNK1/2, SP600125) were
added at a ﬁnal concentration of 10 mM for 1 h prior to the addition
of PMC-II. Cells were harvested 1 h after the addition of 30 mg/ml
PMC-II, and NO2
 and PGE2 levels in the cell culture media
were measured by Greiss assay or ELISA, respectively (C). Data
are expressed as mean SD of four or more separate experi-
ments. **P< 0.05, ***P< 0.01 compared to untreated cells (A) or
PMC-II treated cells (B and C).
467Osteoarthritis and Cartilage Vol. 14, No. 5Levels of serum nitrated collagen-II were reported to
range from w0.125 to 1 nM in patients with RA, from 0.1
to 0.75 nM in OA patients and from w0.01 to 0.25 nM in
age-matched controls28. However, direct quantiﬁcation of
3-nitrotyrosine containing proteins may not accurately re-
ﬂect the true extent of protein nitration in sera or synovial
ﬂuid since 3-nitrotyrosine is known to be taken up by cells
and incorporated into cellular protein74, degraded by inﬂam-
matory mediators such as the neutrophil oxidant hypochlo-
rous acid75 or by ‘denitrase’ enzymes76 and the actual
reported levels of protein nitration may represent an under-
estimate. Therefore in our experiments we exposed chon-
drocytic cells to PMC-II prepared from adding 125 mM
ONOO to collagen-II to yield a ﬁnal 3-nitrotyrosine concen-
tration of 0.1 nM, i.e., at the conservative end of the range
reported for nitrated collagen-II in RA sera28.
The addition of PMC-II to chondrogenically differentiated
MPCs, led to extensive formation of the proinﬂammatory
mediators, NO2
 (as an index of cNO formation) and
PGE2, measured in the culture media 18 h after treatment.
Treatment of cells with established inhibitors of iNOS and
COX-2 substantially reduced the levels of NO2
 and
PGE2, respectively, suggesting that PMC-II stimulated the
synthesis of the inducible forms of NOS and COX (Fig. 3).
Further experiments using speciﬁc commercial ELISAs re-
vealed that PMC-II markedly elevated the protein levels of
iNOS and COX-2 proteins (Fig. 3) and experiments with
speciﬁc inhibitors of iNOS and COX-2 markedly reduced
the levels of NO2
 and PGE2 in the culture media further
conﬁrming the induction of iNOS and COX-2 proteins. Since
these inducible proteins are reported to be regulated at the
transcriptional level by NF-kB through an MAPK signaling
pathway, we next investigated the effects of PMC-II on
the activation of NF-kB and on the phosphorylation of
ERK1/2, p38 and JNK1/2, and MAPK is known to be in-
volved with NF-kB signaling as well as iNOS and COX-2
synthesis. PMC-II (30 mg/ml) rapidly induced thephosphorylation of p38 and ERK1/2 and to a lesser extent
JNK1/2 as well as the nuclear accumulation of the p65 sub-
unit of the transcription factor NF-kB. Inhibitors of p38 and
ERK1/2 reduced MAPK phosphorylation as well as NF-kB
induction, synthesis of COX-2 and iNOS proteins as well
as reduced the levels of NO2
 and PGE2 in the culture me-
dium. These data strongly suggest that PMC-II induced cNO
and PGE2 formation was via iNOS and COX-2 activation
and dependent on a p38, ERK1/2 and NF-kB-dependent
pathway.
There is an intense amount of interest in the MAPK/
NF-kB signaling pathways in RA and OA as they represent
potential targets to inhibit joint erosion in these diseases in
particular their interaction with iNOS and COX-2 pro-
teins32e34. Therefore understanding the mechanisms by
which iNOS and COX-2 are induced in OA and RA is of
considerable importance. Elevated levels of PGE2,
cNO
and ONOO are observed in OA and RA and the addition
of ONOO to cultured human cells leads to the phosphory-
lation of MAPK and NF-kB activation and MAPK pathways
mediate NF-kB activation and COX-2 and iNOS protein ex-
pression. Our data suggest a novel mechanism for RNS-in-
duced cNO and PGE2 synthesis in the inﬂamed and
degenerating human joint, through RNS-mediated protein
modiﬁcation of collagen-II. These ﬁndings are relevant to
clinical observations since 3-nitrotyrosine containing colla-
gen-II was recently discovered in the sera from OA patients.
Activation of NF-kB is observed in the inﬂamed synovium
and the surrounding tissues in arthropathies36e38, inhibitors
of NF-kB reduce joint swelling as well as joint erosion in ex-
perimental models of arthritis47 and inﬂammation48 and also
reduce the protein levels of iNOS, COX-2 and 3-nitrotyro-
sine49 and ONOO inhibitors reduce joint erosion18,19.
Phosphorylation of p38 is known to be involved in NF-kB
activation during chronic inﬂammation77,78 as well as in in-
terleukin (IL)-1b-mediated chondrocyte COX-240,79, iNOS
expression80e82 and concomitant PGE2 and
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Fig. 6. Summary of the potential role of PMC-II in the inﬂamed and degenerating human joint: a vicious circle. (A) Chondrocytes or precursor
cells (MPCs) synthesize collagen-II. (B) In response to an initiating event inﬂammatory cells release cytokines to stimulate iNOS and COX-2
synthesis (reviewed in Ref.33e35). (C) cNO and O2
c are produced by inﬂammatory and joint cells to make ONOO (D). (E) ONOO nitrates
oxidize collagen-II which stimulate the phosphorylation of MAPKs p38 and ERK1/2 (F) which activate the proinﬂammatory transcription factor
NF-kB inducing the synthesis of iNOS and COX-2 proteins resulting in cNO and PGE2 formation. Inhibition of p38 (G), ERK1/2 (H) or NF-kB (I)
prevents transcription of iNOS and COX-2 proteins resulting in reduced levels of cNO and PGE2 as well as exerting anti-inﬂammatory and joint
sparing effects in vivo40e48. SOD mimetics remove O2
c and ONOO scavengers (J), prevent protein nitration and joint degradation18,19. cNO
and ONOO synthesis can also be prevented using iNOS inhibitors (K; Refs. 16,17) and synthesis of PGE2 reduced with inhibitors of COX-2
(L; Refs. 29e31).
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L-modiﬁed collagen-IIformation40. In IL-17 treated chondrocytes, NF-kB activation
and iNOS expression are dependent on the activation of
ERK1/2 and p3841,42. Inhibitors of p38, ERK1/2 and NF-
kB also prevent iNOS and COX-2 activation43,44,46,81 further
suggesting cNO and PGE2 synthesis is regulated through
MAPK and NF-kB. It is tempting to speculate that the pro-
tective effects of ONOO scavengers observed in Refs.
18,19 were due to limiting ONOO-mediated collagen-II ni-
tration/oxidation and subsequent cNO and PGE2 formation,
although further work is required to substantiate this
hypothesis.
In summary (Fig. 6), this study has shown for the ﬁrst time
that PMC-II is not solely a marker for OA and RA disease
activity28 but elicits potentially proinﬂammatory effects on
human cells. PMC-II may also represent a novel mecha-
nism for cNO and PGE2 synthesis in inﬂammatory and de-
generative joint diseases.
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